Skip to content
D2V Clinical logo — Expertise that Translates INDs into Clinical Milestones

D2V Clinical

Expertise that Translates INDs into Clinical Milestones

Founded 2019 United States Raleigh, United States 24 employees Series A Total: $10.00M Biotechnology, Health Care

General Information

Company Name D2V Clinical
Founded Year 2019
Location United States Raleigh, United States
Founders / Decision Makers
Team member
Employees 24
Industries Biotechnology, Health Care
Funding Stage Series A
Business Model B2B, Platform
Revenue Model Service Fee, Consulting Fee, Project Based
Social

BounceWatch is an independent company data service, not affiliated with D2V Clinical. To contact D2V Clinical, visit d2vclinical.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does D2V Clinical compare?

A PDF of D2V Clinical and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting D2V Clinical soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About D2V Clinical

D2V Clinical, founded in 2019, stands at the forefront of biopharmaceutical development, particularly in oncology, hematology, and rare diseases. Based in the United States, this full-service global Contract Research Organization (CRO) partners with biotech companies primarily in the US and China.

With a proven track record, D2V Clinical leverages over 20 years of industry leadership to advance biopharmaceutical value creation, helping eradicate diseases that have unmet medical needs. Their robust network of principal investigators and access to electronic medical records facilitate expedited patient enrollment, smoothing the road to efficient clinical studies.

Their recent $10.00M Series A investment on 23 August 2022, backed by notable investors like Delian Capital, Ming Bioventures, and Suzhou Industrial Park Hongfeng Venture Capital, underscores market confidence in their mission. As they enhance drug development through strategic insights and risk management, D2V Clinical emerges as a crucial ally in accelerating breakthrough treatments to market.

Business keywords: oncology, hematology, rare disease, drug development, biopharmaceutical, CRO, clinical research, investor value creation, global marketing approval, real-time data analysis, clinical development services, biotechnology companies, China market access, patient enrollment, EMR data access

Services & Products

Clinical Research Organization (CRO) Services
Regulatory Affairs Consulting
Clinical Operations Management
Pharmacovigilance Services
Biometric Analysis
Project Management for Clinical Trials
Early Clinical Development Programs

Target Customers

Biotech Companies Pharmaceutical Companies Clinical Drug Developers Healthcare Investors

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $10.00M 3
Delian Capital, Ming Bioventures +1
23 Aug 2022
Seed Round Undisclosed 1
Legend Star
01 Feb 2022
Angel Round Undisclosed 1
Suzhou Industrial Park Hongfeng Venture Capital
01 Jan 2019

D2V Clinical Alternatives & Competitors

View All Alternatives
D2V Clinical vs

Innovating metastatic breast cancer treatment through advanced nanotechnology solutions.

Series C
Biotechnology, Health Care
D2V Clinical vs

Your strategic partner in advancing patient health

Private Equity
81 employees
Biotechnology, Health Care
D2V Clinical vs
Forma Therapeutics
Forma Therapeutics United States

Dedicated to transforming the lives of patients with rare hematologic diseases and cancers.

Series D
159 employees
Biotechnology, Health Care

FAQ About D2V Clinical

Expertise that Translates INDs into Clinical Milestones
D2V Clinical was founded in 2019.
D2V Clinical is headquartered in Raleigh, United States.
D2V Clinical operates in Biotechnology and Health Care. Its work centres on oncology, hematology, rare disease and drug development. Its customers include Biotech Companies, Pharmaceutical Companies and Clinical Drug Developers.
D2V Clinical has a B2B and Platform business model. Its revenue comes from Service Fee, Consulting Fee and Project Based.
D2V Clinical has approximately 24 employees.
D2V Clinical has completed 3 funding rounds, raising a total of $10.00M. The latest funding stage is Series A.
D2V Clinical offers: Clinical Research Organization (CRO) Services, Regulatory Affairs Consulting, Clinical Operations Management, Pharmacovigilance Services, Biometric Analysis, Project Management for Clinical Trials, Early Clinical Development Programs.
Top alternatives and competitors to D2V Clinical include Sopherion Therapeutics, TMC Pharma Services Ltd, Forma Therapeutics, Apollo Therapeutics, Soligenix, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
D2V Clinical and Sopherion Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for D2V Clinical, https://bouncewatch.com/company/d2v-clinical, updated 18 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout